Assessment of Lung Cancer Risk on the Basis of a Biomarker Panel of Circulating Proteins
Florence Guida, Nan Sun, Leonidas E Bantis, David C Muller, Peng Li, Ayumu Taguchi, Dilsher Dhillon, Deepali L Kundnani, Nikul J Patel, Qingxiang Yan, Graham Byrnes, Karel GM Moons, Anne Tjonneland, Salvatore Panico, Claudia Agnoli, Paolo Vineis, Domenico Palli, Bas Bueno-de-Mesquita, Petra H Peeters, Antonio Agudo Show all
JAMA Oncology | AMER MEDICAL ASSOC | Published : 2018
Awarded by National Cancer Institute
Awarded by Fondation ARC pour la recherche sur le cancer
Awarded by ISCIII of the Spanish Ministry of Health
This study was supported by grants 1U19CA203654 and UO1194733 from the National Cancer Institute and the National Cancer Institute Early Detection Research Network, grant INCa_ARC_10450 from Fondation ARC pour la recherche sur le cancer and INCa, the MD Anderson Lung Cancer Moon Shot Program and the Lyda Hill Foundation, the Canary Foundation, the Lungevity Foundation, and the S. Rubenstein Family Foundation. The EPIC study has been supported by the Europe Against Cancer Program of the European Commission (SANCO); Deutsche Krebshilfe; Deutsches Krebsforschungszentrum; German Federal Ministry of Education and Research; Danish Cancer Society; Health Research Fund (FIS) of the Spanish Ministry of Health; Spanish Regional Governments of Andalucia, Asturias, Basque Country, Murcia, and Navarra; Catalan Institute of Oncology, Spain; grant RETICC DR06/0020 from the ISCIII of the Spanish Ministry of Health; Cancer Research UK; Medical Research Council, United Kingdom; Greek Ministry of Health; Stavros Niarchos Foundation; Hellenic Health Foundation; Italian Association for Research on Cancer (AIRC); Italian National Research Council; Fondazione-Istituto Banco Napoli, Italy; Associazione Italiana per la Ricerca sul Cancro-AIRC-Milan; Compagnia di San Paolo; Dutch Ministry of Public Health, Welfare, and Sports; World Cancer Research Fund; Swedish Cancer Society; Swedish Scientific Council; Regional Government of Vasterbotten, Sweden; NordForsk (Centre of excellence programme HELGA), Norway; French League against Cancer (LNCC), France; National Institute for Health and Medical Research (INSERM), France; Mutuelle Generale de l'Education Nationale (MGEN), France; 3M Co, France; Gustave Roussy Institute (IGR), France; and General Councils of France.